Recently added

A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer

Doger, Bernard; Peer, Avivit ; Sarid, David; Eigl, Bernhard; Calvo, Emiliano; Carles, Joan (Oxford University Press, 2025-01-20)

Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL

Pavlova, Sarka; Malcikova, Jitka; Radova, Lenka; Bonfiglio, Silvia; Cowland, Jack Bernard; Brieghel, Christian; Blanco, Adoracion; Abrisqueta, Pau; Tazon-Vega, Barbara (Wiley, 2025-01)

Mortality in chronic pulmonary aspergillosis: a systematic review and individual patient data meta-analysis

Sengupta, Abhinav; Ray, Animesh; Upadhyay, Ashish Datt; Izumikawa, Koichi; Tashiro, Masato; Kimura, Yuya; Aguilar-Company, Juan (Elsevier, 2025-03)

Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial

Bex, Axel; Russo, Paul; Tomita, Yoshihiko; Cutuli, Hernan Javier; Rojas, Carlos; Motzer, Robert; Suárez, Cristina (American Society of Clinical Oncology, 2025-01-10)

FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)

Cho, Byoung Chul; Goto, Koichi; Johnson, Melissa; Garon, Edward; FELIP, ENRIQUETA; Spira, Alexander (Elsevier, 2025-01)

Scientia. Department of Health Digital Information Depot

VHIO - Articles científics: Recent submissions

A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer

Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL

Mortality in chronic pulmonary aspergillosis: a systematic review and individual patient data meta-analysis

Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial

FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)

Scientia. Department of Health Digital Information Depot

VHIO - Articles científics: Recent submissions

A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer ﻿

Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL ﻿

Mortality in chronic pulmonary aspergillosis: a systematic review and individual patient data meta-analysis ﻿

Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial ﻿

FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004) ﻿

A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer

Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL

Mortality in chronic pulmonary aspergillosis: a systematic review and individual patient data meta-analysis

Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial

FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)